Evaluating investments in typhoid vaccines in two slums in Kolkata, India

Journal of Health, Population and Nutrition

Volumn 27, Issue 6, 2009, Pages 711-724

  Cook, Joseph ^a   Sur, Dipika ^b   Clemens, John ^c   Whittington, Dale ^d,e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^c International Vaccine Institute   (South Korea)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Cost benefit analysis; Costs and cost analysis; Evaluation studies; India; Slums; Typhoid; Typhoid vaccine

Indexed keywords

TYPHOID PARATYPHOID VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COST BENEFIT ANALYSIS; COST OF ILLNESS; ECONOMICS; FEE; HEALTH SERVICE; HUMAN; INCIDENCE; INDIA; INFANT; POVERTY; PRESCHOOL CHILD; PUBLIC HEALTH; TYPHOID FEVER;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEES AND CHARGES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INCIDENCE; INDIA; INFANT; POVERTY; POVERTY AREAS; PUBLIC HEALTH; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; YOUNG ADULT;

EID: 77449099191     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Costeffectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007;369:389-96.
2. Podewils LJ, Antil L, Hummelman E, Bresee J, Parashar UD, Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005;192(Suppl 1):S133-45.
3. Cook J, Jeuland M, Maskery B, Lauria D, Sur D, Clemens J et al. Re-visiting socially-optimal vaccine subsidies: an empirical application in Kolkata, India. J Policy Anal Manage 2009;28:6-28.
4. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med 2002;347:1770-82
5. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004;82:346-53
6. Hessel L, Debois H, Fletcher M, Dumas R. Experience with Salmonella typhi Vi capsular polysaccharide vaccine. Eur J Clin Microbiol Infect Dis 1999;18:609-20.
7. Yang HH, Kilgore PE, Yang LH, Park JK, Pan YF, Kim Y et al. An outbreak of typhoid fever,Xing-An county, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine.J Infect Dis 2001;183:1775-80.
8. Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001;79:625-31.
9. Acosta CJ, Galindo CM, Deen JL, Ochiai RL, Lee HJ, von Seidlein L et al. Vaccines against cholera, typhoid fever and shigellosis for developing countries. Exp Opin Biol Ther 2004;4:1939-51.
10. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. N Engl J Med 1987;317:1101-4.
11. Papadimitropoulos V, Vergidis PI, Bliziotis I, Falagas ME. Vaccination against typhoid fever in travellers: a cost-effectiveness approach. Clin Microbiol Infect 2004;10:681-3.
12. Poulos C, Bahl R, Whittington D, Bhan MK, Clemens JD, Acosta CJ. A cost-benefit analysis of typhoid fever immunization programs in an Indian urban slum community. J Health Popul Nutr 2004;22:311-21.
13. Canh DG, Whittington D, Le TK, Utomo N, Nguyen TH, Poulos C, Dang TD et al. Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy Plan 2006;21:241-55.
14. Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008;26:6305-16.
15. Zerbe RO, Jr., editor. Benefit-cost analysis. 1st ed. Northhampton, MA: Edward Elgar Publishing, 2008.1,088 p.
16. Boardman A, Greenberg DH, Vining A, Weimer DL. Cost-benefit analysis: concepts and practices. 3rd ed. Upper Saddle River, NJ: Prentice-Hall, 2005. 576 p.
17. Lucas M, Jeuland M, Deen J, Lazaro N, MacMahon M,Nyamete A et al. Private demand for cholera vaccines in Beira, Mozambique. Vaccine 2007;25:2599-609.
18. Kundu N. Understanding slums: case studies for the global report on human settlements, 2003. The case of Kolkata, India. London: Development Planning Unit, University College London, 2006. 21 p.
19. Ochiai RL, Acosta CJ, Danovaro-Holliday MC, Baiqing D, Bhattacharya SK, Agtini MD et al. A study of ctyphoid fever in five Asian countries: disease burden and implications for control. Bull World Health Organ 2008;86:260-8.
20. Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. N Engl J Med 2009; 361:335-44.
21. World Health Organization. Typhoid fever. 2007.(http://www.who.int/topics/typhoid_fever/en, accessed on 1 March 2008).
22. World Health Organization. Typhoid fever, Democratic Republic of the Congo. Weekly Epidemiol Rec 2005;80:30-31.
23. Edejer T T-T, Baltussen R, Adam T, Torres TT, Hutubessy Acharya RA, Evans DB, et al., editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003. 312 p.]
24. Registrar General of India. Census of India. New Delhi: Registrar General of India, 2001. (http://www. censusindia.net, accessed on 1 March 2008).
25. Whittington D, Sur D, Cook J, Chatterjee S, Maskery B, Lahiri M et al. Rethinking cholera and typhoid vaccination policies for the poor: private demand in Kolkata, India. World Dev 2009;37:399-409.
26. Naficy A, Rao MR, Paquet C, Antona D, Sorkin A,Clemens JD. Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings: a cost-effectiveness analysis. JAMA 1998;279:521-5.
27. Cookson ST, Stamboulian D, Demonte J, Quero L,Martinez de Arquiza C, Aleman A et al. A cost-benefitanalysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population.
28. United Nations Educational, Scientific and Cultural Organization. Statistics on primary and secondary net enrollment. Quebec: UNESCO Institute for Statistics,2008. (http://stats.uis.unesco.org, accessed on 1 October 2008).
29. Mathers CD, Vos T, Lopez AD, Salomon J, Ezzati M. National burden of disease studies: a practical guide.2.0 ed. Geneva: Global Programme on Evidence for Health Policy, World Health Organization, 2001. 137p.
30. Bhattacharya S, Alberini A, Cropper ML. The value of mortality risk reductions in Delhi, India. J Risk Uncertainty 2007;34:21-47.
31. World Bank. World development report 1993: investing in health. New York, NY: Oxford University Press, 1993. 344 p.
32. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB et al., editors. Disease control priorities in developing countries. 2nd ed. New York, NY: Oxford University Press, 2006. 1,400p.
33. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M et al. Advancement of global health: key messages from the Diseases Control Priorities Project. Lancet 2006;367:1193-208.
34. World Health Organization. World health statistics 2007. Geneva: World Health Organization, 2007. 80 p. (http://www.who.int/whosis/en/, accessed on 1 December 2007).
35. India. Ministry of Health and Family Welfare. National Health Accounts Cell. National health accounts, India, 2001-2002. New Delhi: IG Printers Pvt. Ltd., 2005. 79 p.(http://www.mohfw.nic.in/NHA%202001-02.pdf, accessed on 1 March 2008).
36. Deolalikar AB, Jamison DT, Jha P, Laxminarayan R. Financing health improvements in India. Health Aff 2008;27:978-90.
37. van Doorslaer E, O'Donnell O, Rannan-Eliya RP, Somanathan A, Adhikari SR, Garg CC et al. Catastrophic payments for health care in Asia. Health Econ 2007;16:1159-84.
38. Lauria DT, Maskery B, Poulos C, Whittington D. An optimization model for reducing typhoid cases in developing countries without increasing public spending. Vaccine 2009;27:1609-21.